$OTLK Outlook Therapeutics up 12% premarket, loads more to come.

This was a real winner yesterday and today is going to be the same, already up 12% pre market, we think there should be continuation in this name for days to come.
Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer

OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.